The University of Texas Health Science Center, Houston
Loma Linda University
Minnesota Oral & Facial Surgery
University of Alabama at Birmingham
The study objectives are to:
1. Evaluate STRATICYTE™ sensitivity and specificity in a cohort of patients that meet the inclusion/exclusion criteria.
2. Identify patient and clinical characteristics influencing the sensitivity and specificity of the STRATICYTE™ model.
3. Estimate the correlation between STRATICYTE™ outcome and time to a positive diagnosis of oral cancer.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
From the archive, any patient who presents with clinically evident oral lesions and biopsy-proven dysplasia (punch or scalpel biopsies; any grade or classification system)
Patients with initial oral lesions with epithelial atypia suspicious for neoplasia, with:
No histological evidence of cancer with clinical follow-up data for a period of at least five years; or
OSCC development (histologic or documented evidence of invasive cancer).
Patients who had archived biopsy tissue blocks of a previous oral lesion(s) meeting the above criteria and retained at the same clinical center.
You may not be if
Patients with oral lesions or dysplasia with no indication of OSCC development or follow-up data of less than five years in non-OSCC patients.
Patients diagnosed with oral epithelial dysplasia concomitant with OSCC at the time of the biopsy's original pathology report or a subsequent clinical note of cancer progression within three months post-biopsy.
Clareo Health | Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™
